ADCT
ADC Therapeutics SA
1.30$
-1.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +15.8% | +7.5% | -3.6% | +6.1% | -8.4% | +36.2% | -18.2% | -12.8% | +40.4% | -13.1% | -3.9% | – | |
| – | +34,092.6% | -98.0% | -51.5% | -30.1% | +61.1% | +50.3% | -59.4% | +43.8% | +41.3% | +112.8% | -35.0% | – | |
| – | -867.0% | – | +4.2% | +8.8% | -11.8% | +35.0% | -14.2% | -15.4% | +40.3% | -23.1% | +2.9% | – | |
| – | +6.6% | -15.2% | -5.6% | +33.8% | -16.6% | +6.7% | +4.0% | -10.9% | -32.2% | +9.3% | -12.6% | – | |
| – | -25.0% | +55.9% | -8.6% | -2.9% | -3.0% | -34.3% | +50.3% | -6.3% | +11.2% | -36.5% | -2.0% | – | |
| – | -232.7% | – | -8.0% | +17.6% | -9.8% | +3.0% | +25.7% | -26.7% | -13.3% | +5.5% | +1.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -40.7% | +62.8% | +1.5% | +3.5% | -9.1% | +2.6% | +6.3% | +3.0% | -2.8% | -5.1% | +9.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -99.6% | +43.6% | -61.5% | -456.7% | – | +660.0% | -121.2% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -423.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.